MA50189A - Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci - Google Patents

Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Info

Publication number
MA50189A
MA50189A MA050189A MA50189A MA50189A MA 50189 A MA50189 A MA 50189A MA 050189 A MA050189 A MA 050189A MA 50189 A MA50189 A MA 50189A MA 50189 A MA50189 A MA 50189A
Authority
MA
Morocco
Prior art keywords
abiraterone
administering
processes
forming
same
Prior art date
Application number
MA050189A
Other languages
English (en)
Inventor
Urvi Gala
Dave Miller
Original Assignee
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies Llc filed Critical Dispersol Technologies Llc
Publication of MA50189A publication Critical patent/MA50189A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA050189A 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci MA50189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562081P 2017-09-22 2017-09-22

Publications (1)

Publication Number Publication Date
MA50189A true MA50189A (fr) 2021-05-19

Family

ID=65808544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050189A MA50189A (fr) 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Country Status (10)

Country Link
US (1) US20190091339A1 (fr)
EP (1) EP3684371A4 (fr)
JP (2) JP2020534320A (fr)
KR (1) KR20200064993A (fr)
CN (1) CN111107852A (fr)
AU (1) AU2018335391A1 (fr)
CA (1) CA3075095A1 (fr)
IL (1) IL273125A (fr)
MA (1) MA50189A (fr)
WO (1) WO2019060525A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021018540A2 (pt) * 2019-03-18 2021-11-30 Univ Texas Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente
CN110141556B (zh) * 2019-06-24 2021-07-13 李建恒 一种阿比特龙包合物片剂及其制备方法
US20210128536A1 (en) * 2019-11-01 2021-05-06 Dispersol Technologies, Llc Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
CA3160834A1 (fr) * 2019-11-14 2021-05-20 Suven Life Sciences Limited Compositions pharmaceutiques amorphes d'acetate d'abiraterone
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
KR102363026B1 (ko) * 2019-12-26 2022-02-16 보령제약 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697099C (fr) * 2007-08-21 2018-02-20 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
US9040080B2 (en) * 2008-10-21 2015-05-26 Southwest Research Institute Processing of heat-sensitive active agents
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
WO2013079964A1 (fr) * 2011-11-30 2013-06-06 Astrazeneca Ab Traitement combiné du cancer
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (fr) * 2012-07-11 2014-01-16 Sandoz Ag Stabilité d'oxydation d'acétate d'abiratérone
PL2969227T3 (pl) * 2013-03-15 2019-12-31 Sun Pharma Global Fze Formulacja octanu abirateronu
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone
US20170319539A1 (en) * 2014-10-01 2017-11-09 Mylan Laboratories Ltd. Amorphous Empagliflozin
WO2017037647A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Compositions pharmaceutiques stables d'abiratérone

Also Published As

Publication number Publication date
JP2020534320A (ja) 2020-11-26
WO2019060525A1 (fr) 2019-03-28
IL273125A (en) 2020-04-30
JP2023182674A (ja) 2023-12-26
EP3684371A1 (fr) 2020-07-29
AU2018335391A1 (en) 2020-03-26
KR20200064993A (ko) 2020-06-08
EP3684371A4 (fr) 2021-05-19
CN111107852A (zh) 2020-05-05
CA3075095A1 (fr) 2019-03-28
US20190091339A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
IL275704A (en) Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
MA51617A (fr) Mécanisme d'administration de médicament
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
IL270812B1 (en) Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2018015985A (es) Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MA55015A (fr) Formulations pharmaceutiques
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
WO2016040814A3 (fr) Polymères de bisulfure et procédés d'utilisation associés
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
EP3881843A4 (fr) Agent prophylactique ou thérapeutique et composition médicinale contre une maladie à médiation par l'il-31
GB201910294D0 (en) Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate
MA53099A (fr) Formes d'ivosidénib et compositions pharmaceutiques
IL286416A (en) Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
IL285073A (en) Concentrated liquid pharmaceutical preparations of furosemide and methods of administering these preparations
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
PL3880171T3 (pl) Doustny preparat farmaceutyczny zawierający ibuprofen
SG11202101547WA (en) Pharmaceutical composition for oral administration